Gilead Sciences Price Target Raised to $188.00/Share From $165.00 by Citigroup

What happened

Citigroup raised its price target on Gilead Sciences to $188.00 per share from $165.00, while maintaining a Buy rating on the stock, according to Benzinga ratings actions.

Confirmed

Global impact / market context

A higher price target means Citigroup analysts now expect Gilead shares to reach a higher level, which can draw investor attention and support demand for the stock, though a target is an estimate, not a guarantee of future performance.

Analyst inference

Analyst rating changes are common in stock markets and often shape how investors view a company's near-term prospects, because a maintained Buy rating signals continued positive analyst opinion even as the target price is adjusted upward.

Analyst inference

What to watch

1. Citigroup maintained its Buy rating on Gilead Sciences alongside the target increase, so the rating itself did not change in this update. Confirmed
2. Investors could compare this $188.00 target with targets from other analysts covering Gilead to see whether views on the stock are broadly aligned. Proposed
3. Watch whether Gilead's shares move toward the new target, since a raised target can influence investor positioning but does not by itself change company earnings or cash flow. Analyst inference

Evidence

• Original source link unavailable